Business
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nPresentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic strategies in lung cancer\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests and real-world data will be presented at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022), hosted by the International Association for the Study of Lung Cancer, August 6-9 in Vienna, Austria. Among the 10 abstracts are oral presentations and posters highlighting the use of Guardant360™ to help physicians inform treatment decisions, GuardantOMNI™ to advance cancer therapy trials, and GuardantINFORM™ for targeted drug development to improve outcomes for patients with lung cancer.\n\n“We look forward to sharing new data at WCLC that demonstrate the utility of our liquid biopsy tests and datasets to create more accurate tumor profiles and impact outcomes for lung cancer patients around the world,” said Helmy Eltoukhy, Guardant Health co-CEO. “The data from retrospective and real-world analyses will show how blood-based tests provide critical insights into tumor evolution and treatment resistance throughout each lung cancer patient’s treatment journey and contribute more broadly to further developing the field of thoracic oncology.”\n\nFull List of Presentations:\n\nGuardant360\n\n\nClinical and molecular profile of patients with non-small cell lung cancer (NSCLC) with incidental pathogenic germline variants detected in cfDNA (oral)\n\n\nPatterns of KEAP1 genomic co-alterations in advanced lung cancer as identified by plasma-based genotyping (e-poster)\n\n\nGermline HRR mutations in metastatic NSCLC and impact on progression-free survival: A single-center retrospective study (e-poster)\n\n\nTargetable alterations in non-small cell lung cancer according to age and sex (e-poster)\n\n\nLiquid biopsies first to make treatment decisions in patients with metastatic non-small cell lung cancer (NSCLC) (e-poster)\n\n\nLandscape of EGFR extracellular domain mutations in advanced non-small cell lung carcinoma (e-poster)\n\n\nThe patient impact of liquid biopsy – health-related quality of life in patients undergoing...